SBIR/STTR Research Award

A nanoparticle delivery system for CRISPR Cas based therapeutics

Award identifier 542cc2be29b318fa22f1c1aba2beb7011de9ac8e4ab4ae591ebaef983b54380bAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

STTR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ATGC Inc.
Proposal award date
2017-06-01
Contract end date
2018-07-31
UEI
F3KRQG95DCF6
Solicitation number
PA14-308
Topic code
NCATS

Research abstract

Abstract Applications of customizable nucleases such as CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein have enabled efficient and precise gene correction in vitro and hold promises for eventually achieving in vivo gene correction therapy However to apply CRISPR Cas in therapeutic settings several major challenges remain to be addressed i homologous recombination HR even with the help of Cas is still of low efficiency ii Cas is associated with off target effects and iii there is a lack of an efficient virus free system to deliver CRISPR Cas elements in vivo The present proposal focuses on the challenge of lack of an efficient non viral in vivo delivery system We recently developed novel hyperbranched polymers HPs with high nucleic acid binding affinity negligible cytotoxicity and achieved satisfactory delivery of microRNAs both in vitro and in vivo Here we propose to develop hyperbranched HP based system for effective delivery of Cas plasmid DNA pDNA In Phase I we will work to formulate and test new HPs for effectively packaging of Cas pDNA and evaluate the safety and efficacy of these HPs in vitro In Phase II we will expand the capability of HPs for Cas in vivo and apply HPs for Cas therapeutics in animal models Success of the proposed work will have significant impacts on basic and translational research and accelerate the development of Cas therapeutics Project Narrative One major challenge for CRISPR clustered regularly interspaced short palindromic repeats Cas CRISPR associated protein therapeutics is the lack of an efficient non viral in vivo delivery system The present work aims to develop a nanopolymer platform for delivery of Cas plasmid DNA both in vitro and in vivo Success of the proposed work will have significant impacts on basic and translational research and accelerate the development of Cas therapeutics

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2017–2023). Reported award amounts total $4,801,284. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.